Empagliflozin/Linagliptin
Brand name: Glyxambi
Rank #329 of 500 drugs by total cost
$32.6M
Total Cost
34,331
Total Claims
$32.6M
Total Cost
1,387
Prescribers
$950
Cost per Claim
2,796
Beneficiaries
53,325
30-Day Fills
$24K
Avg Cost/Provider
25
Avg Claims/Provider
About Empagliflozin/Linagliptin
Empagliflozin/Linagliptin (sold as Glyxambi) was prescribed 34,331 times by 1,387 Medicare Part D providers in 2023, costing the program $32.6M. At $950 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 326 | Morphine Sulfate (Morphine Sulfate Er) | $33.2M | 1,023,056 |
| 327 | Budesonide (Budesonide Dr) | $33.1M | 120,202 |
| 328 | Mavacamten (Camzyos) | $32.8M | 3,969 |
| 329 | Empagliflozin/Linagliptin (Glyxambi) | $32.6M | 34,331 |
| 330 | Methotrexate Sodium (Methotrexate) | $32.4M | 911,965 |
| 331 | Bumetanide (Bumetanide) | $32.4M | 735,077 |
| 332 | Voxelotor (Oxbryta) | $31.5M | 2,707 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology